Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis

V. I. Turobov, Alexey Danilkovich, А. Б. Шевелев, Yulia K. Biryukova, Natalia V. Pozdniakova, В. Н. Азев, А. Н. Мурашев, Valery M. Lipkin, Igor P. UdovichenkoFrontiers in Pharmacology 2018 · DOI

Abstract

Immunocortin is a synthetic peptide corresponding to amino acid residues 11-20 of the variable region of the human immunoglobulin G1 (IgG1) heavy chain. Previous studies indicated its ability to inhibit phagocytosis and T-lymphocyte proliferation. This study investigates the therapeutic potential of immunocortin in Dark Agouti (DA) rats with induced experimental autoimmune encephalomyelitis (EAE), a standard model for Multiple Sclerosis. Results demonstrate that daily intraperitoneal administration of immunocortin (100 μg/animal) significantly reduces clinical symptoms and inflammatory infiltration in the central nervous system, suggesting a novel endogenous-based approach for treating autoimmune disorders.

Introduction

Multiple Sclerosis (MS) is a chronic autoimmune disease characterized by immune-mediated destruction of the myelin sheath. Current therapeutic strategies often involve broad immunosuppression, which can lead to significant side effects. This research explores the use of endogenous peptides—fragments naturally derived from antibody degradation—as targeted immunomodulators. Specifically, the peptide immunocortin (sequence: VKKPGSSVKV) mimics the activity of Adrenocorticotropic Hormone (ACTH), potentially leveraging the body's natural "off-switches" to dampen pathological immune responses.

Methods

The study utilized Dark Agouti (DA) rats, in which EAE was induced via immunization with spinal cord homogenate. Immunocortin was synthesized using solid-phase peptide synthesis and purified by HPLC.

  • In Vivo Treatment: Rats received daily intraperitoneal injections of either immunocortin (400 µg/kg) or a saline control. Clinical severity was monitored daily using a standard 0–5 scoring system.
  • In Vitro Assays: Lymphocytes were isolated from immunized rats to assess the peptide's effect on antigen-induced (Myelin Basic Protein) and mitogen-induced (Concanavalin A) proliferation using $[^3H]$thymidine incorporation.
  • Histopathology: Spinal cord sections were stained to evaluate the degree of inflammatory cell infiltration.

Results

Clinical Efficacy in EAE

The administration of immunocortin led to a significant reduction in the severity of EAE symptoms. While control rats exhibited peak clinical scores near 3.5, indicating severe paralysis, the treated group maintained significantly lower scores throughout the observation period.

Clinical course of EAE in DA rats treated with immunocortin vs. control.

Histological Evidence of Reduced Inflammation

Microscopic examination of spinal cord tissues corroborated the clinical findings. Control animals showed extensive infiltration of inflammatory cells into the nervous tissue. In contrast, rats treated with immunocortin displayed a marked reduction in these infiltrates, preserving the integrity of the spinal cord architecture.

Histological analysis of spinal cord tissue showing reduced inflammatory infiltration in treated rats (B) compared to control (A).

Lymphocyte Proliferation

In vitro experiments confirmed that immunocortin acts as a potent inhibitor of T-cell activation. The peptide effectively suppressed the proliferation of lymphocytes stimulated by both specific myelin antigens and general mitogens, suggesting a fundamental regulatory effect on immune cell expansion.

Discussion

The therapeutic effect of immunocortin likely stems from its "ACTH-like" properties. By binding to ACTH receptors, the peptide may stimulate local or systemic anti-inflammatory pathways. The high degree of sequence homology between this IgG1 fragment and ACTH suggests a mechanism of molecular mimicry that the immune system uses for self-regulation.

While these results are promising, limitations include the slight sequence variation between human and rat IgG, which may affect potency in this specific model. Future research should focus on clarifying the exact signaling pathways involved and evaluating the long-term safety and efficacy of human-sequence immunocortin in clinical settings.

Conclusion

Immunocortin represents a promising candidate for the development of targeted, low-toxicity treatments for Multiple Sclerosis. By utilizing a peptide derived from the body's own antibodies, this approach offers a more "surgical" method of immune modulation compared to traditional immunosuppressants.

Summary updated

Abstract

Peptide immunocortin sequence corresponds to the amino acid residues 11-20 of the variable part of human immunoglobulin G1 (IgG1) heavy chain. Since immunocortin was shown previously to inhibit phagocytosis in peritoneal macrophages and ConA-induced T-lymphocytes proliferation in culture, we suggested that immunocortin administering may be of use for patients with self-immune syndrome. Immunocortin in concentration 10 μM inhibited proliferation of both antigen (myelin)-induced and ConA-induced LN lymphocytes isolated from the lymph nodes of Dark Agouti (DA) rats immunized with chorda shear. The biological trials of the synthetic immunocortin were carried out on the DA rats with induced experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. These <i>in vivo</i> experiments have shown that intraperitoneal injections of immunocortin in a daily dosage 100 μg per animal reduced symptoms of EAE in DA rats.
BibTeX
@inproceedings{turobov2018efficacy,
  author = {V. I. Turobov and Alexey Danilkovich and А. Б. Шевелев and Yulia K. Biryukova and Natalia V. Pozdniakova and В. Н. Азев and А. Н. Мурашев and Valery M. Lipkin and Igor P. Udovichenko},
  title = {{Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2018},
  doi = {10.3389/fphar.2018.00113},
}
Figure